Molecular mechanisms of amyloidosis

New England Journal of Medicine

Volumn 349, Issue 6, 2003, Pages 583-596

  Merlini, Giampaolo ^a   Bellotti, Vittorio ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID PROTEIN; AMYLOID;

AMYLOIDOSIS; BIOCHEMISTRY; CLINICAL PRACTICE; DISEASE TRANSMISSION; DRUG TARGETING; GENE MUTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN SYNTHESIS; REVIEW; TREATMENT PLANNING; BIOSYNTHESIS; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MUTATION; SENILE PLAQUE;

AMYLOID; AMYLOIDOSIS; HUMANS; MUTATION; PROTEIN CONFORMATION; SENILE PLAQUES;

EID: 0042709605     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra023144     Document Type: Review

References (114)

1. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibfil protein nomenclature - 2002. Amyloid 2002;9:197-200.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
3. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64.
4. Prusiner SB. Shattuck Lecture - neurodegenerative diseases and prions. N Engl J Med 2001;344:1516-26.
5. Drueke TB. Beta2-microglobulin and amyloidosis. Nephrol Dial Transplant 2000;15:Suppl 1:17-24.
6. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79:1817-22.
7. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91.
8. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
9. Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 1971;172:1150-1.
10. Sunde M, Blake CC. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q Rev Biophys 1998;31:1-39.
11. Dobson CM. Getting out of shape. Nature 2002;418:729-30.
12. Perutz ME. Amyloid fibrils: mutations make enzyme polymerize. Nature 1997;385: 773, 775.
13. Dobson CM, Karplus M. The fundamentals of protein folding: bringing together theory and experiment. Curr Opin Struct Biol 1999;9:92-101.
14. Schultz CP. Illuminating folding intermediates. Nat Struct Biol 2000;7:7-10.
15. Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 2001;498:201-3.
16. Verdone G, Corazza A, Viglino P, et al. The solution structure of human beta2-microglobulin raveals the prodromes of its amyloid transition. Protein Sci 2002;11:487-99.
17. Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med 2000;51:543-69.
18. McLaurin J, Yang D, Yip CM, Fraser PE. Modulating factors in amyloid-beta fibril formation. J Struct Biol 2000;130:259-70.
19. Ozaki S, Abe M, Wolfenbarger D, Weiss DT, Solomon A. Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrom's macroglobulinemia. Clin Immunol Immunopathol 1994;71:183-9.
20. Perfetti V, Casarini S, Palladini G, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 2002;100:948-53.
21. Perfetti V, Ubbiali P, Vignarelli MC, et al. Evidence that amyloidogenic light chains undergo antigen-driven selection. Blood 1998;91:2948-54.
22. Hurle MR, Helms LR, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 1994;91:5446-50.
23. Stevens FJ. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 2000;7:200-11.
24. McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995;34:13527-36.
25. Booth DR, Sunde M, Bellotti V, et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 1997;385:787-93.
26. Saraiva MJ. Sporadic cases of hereditary systemic amyloidosis. N Engl J Med 2002;346:1818-9.
27. Pepys MB, Hawkins PN, Booth DR, et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 1993;362:553-7.
28. valleix S, Drunat S, Philit JB, et al. Hereditary renal amyloidosis caused by a new variant lysozyme W64K in a French family. Kidney Int 2002;61:907-12.
29. Booth DR, Pepys MB, Hawkins PN. A novel variant of human lysozyme (T70N) is common in the normal population. Hum Mutat 2000;16;180.
30. Abrahamson M, Grubb A. Increased body temperature accelerates aggregation of the Leu-68→Gln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. Proc Natl Acad Sci U S A 1994;91:1416-20.
31. Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem 1997;50:183-242.
32. Isaacson RL, Weeds AG, Fersht AR. Equilibria and kinetics of folding of gelsolin domain 2 and mutants involved in familial amyloidosis-Finnish type. Proc Natl Acad Sci U S A 1999;96:11247-52.
33. Canet D, Last AM, Tito P, et al. Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat Struct Biol 2002;9:308-15.
34. Almeida MR, Alves IL, Terazaki H, Ando Y, Saraiva MJ. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun 2000;270:1024-8.
35. Esposito G, Garcia J, Mangione P, et al. Structural and folding dynamics properties of T70N variant of human lysozyme. J Biol Chem (in press).
36. Chiti F, Calamai M, Taddei N, Stefani M, Ramponi G, Dobson CM. Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc Natl Acad Sci U S A 2002;99:Suppl 4:16419-26.
37. Kazmirski SL, Howard MJ, Isaacson RL, Fersht AR. Elucidating the mechanism of familial amyloidosis-Finnish type: NMR studies of human gelsolin domain 2. Proc Natl Acad Sci U S A 2000;97:10706-11.
38. Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci 1999;24:329-32.
39. Kim YS, Cape SP, Chi E, et al. Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. J Biol Chem 2001;276:1626-33.
40. Khurana R, Gillespie JR, Talapatra A, et al. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 2001;40:3525-35.
41. Bellotti V, Mangione P, Merlini G. Immunoglobulin light chain amyloidosis the archetype of structural and pathogenic variability. J Struct Biol 2000;130:280-9.
42. Stix B, Kahne T, Sletten K, Raynes J, Roessner A, Rocken C. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol 2001;159:561-70.
43. Chen CD, Huff ME, Matteson J, et al. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J 2001;20:6277-87.
44. Kim SH, Wang R, Gordon DJ, et al. Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nat Neurosci 1999;2:984-8.
45. Carrell RW, Lomas DA. Conformational disease. Lancet 1997;350:134-8.
46. Uversky VN. What does it mean to be natively unfolded? Eur J Biochem 2002;269:2-12.
47. Andreola A, Bellotti V, Giorgetti S, et al. Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein A-I. J Biol Chem 2003;278:244-451.
48. Benson MD, Liepnieks JJ, Yazaki M, et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 2001;72:272-7.
49. Frangione B, Castano EM, Wisniewski T, Ghiso J, Prelli F, Vidal R. Apolipoprotein E and amyloidogenesis. Ciba Found Symp 1996;199:132-41.
50. Yakar S, Livneh A, Kaplan B, Pras M. The molecular basis of reactive amyloidosis. Semin Arthritis Rheum 1995;24:255-61.
51. Lundmark K, Westermark GT, Nystrom S, Murphy CL, Solomon A, Westermark P. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A 2002;99:6979-84.
52. Higuchi K, Hosokawa M, Takeda T. Senescence-accelerated mouse. Methods Enzymol 1999;309:674-86.
53. Elliott-Bryant R, Cathcart ES. Amyloid enhancing factor and dietary transmission in accelerated amyloid A amyloidosis. Clin Immunol Immunopathol 1998;88:65-9.
54. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993;73:1055-8.
55. Morozova-Roche LA, Zurdo J, Spencer A, et al. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J Struct Biol 2000;130:339-51.
56. Naiki H, Hashimoto N, Suzuki S, Kimura H, Nakakuki K, Geiko F. Establishment of a kinetic model of dialysis-related fibril extension in vitro. Amyloid 1997;4:223-32.
57. Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients wtih familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002;73:745-51.
58. Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000;274:702-6.
59. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component: a critical review. Amyloid 1997;4:274-95.
60. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988;1:1413-8.
61. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995;92:4299-303.
62. Kisilevsky R. Amyloidogenesis - unquestioned answers and unanswered questions. J Struct Biol 2000;130:99-108.
63. Snow AD, Kisilevsky R, Stephens C, Anastassiades T. Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation: qualitative and quantitative analysis. Lab Invest 1987;56:665-75.
64. Gallo G, Wisniewski T, Choi-Miura NH, Ghiso J, Frangione B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994;145:526-30.
65. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997;278:1349-56.
66. Stevens FJ, Kisilevsky R. Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell Mol Life Sci 2000;57:441-9.
67. Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6:643-51.
68. Harris DL, King E, Ramsland PA, Edmundson AB. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes. J Mol Recognit 2000;13:198-212.
69. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001;98:714-20.
70. Sousa MM, Du YS, Fernandes R, Guimaraes A, Stern D, Saraiva MJ. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001;21:7576-86.
71. Rogers J, Webster S, Lue LF, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996;17:681-6.
72. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95:6448-53.
73. Hartley DM, Walsh DM, Ye CP, et al. Protofibrillar intermediates of amyloid betaprotein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999;19:8876-84.
74. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159:1993-2000.
75. Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 2002;294:309-14.
76. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-9.
77. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-6.
78. Dember LM, Sanchorawala V, Seldin DC, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001;134:746-53.
79. Arbustini E, Morbini P, Verga L, et al. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 1997;4:157-70.
80. Murphy CL, Eulitz M, Hrncic R, et al. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol 2001;116:135-42.
81. Demetriades AK. Functional neuroimaging in Alzheimer's type dementia. J Neurol Sci 2002;203-204:247-51.
82. Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995;32:60-79.
83. Gillmore JD, Stangou AJ, Tennent GA, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001;71:986-92.
84. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 2000;6:916-9.
85. Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001;113:1044-6.
86. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol 2000;14:477-98.
87. Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001;345:1748-57.
88. McDermott MF. Genetic clues to understanding periodic fevers, and possible therapies. Trends Mol Med 2002;8:550-4.
89. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000;343:1044-5.
90. Suhr OB, Ericzon BG, Friman S. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl 2002;8:787-94.
91. Ohno S, Yoshimoto M, Honda S, et al. The antisense approach in amyloid light chain amyloidosis: identification of monoclonal Ig and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models. J Immunol 2002;169:4039-45.
92. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20:1006-10.
93. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A 1996;93:15051-6.
94. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000;7:312-21.
95. Wolfe MS. Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem 2001;44:2039-60.
96. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31. [Erratum, Lancet 2001;357:562.]
97. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-6.
98. Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem 2002;2:417-23.
99. Davis PD, Raffen R, Dul LJ, et al. Inhibition of amyloid fiber assembly by both BiP and its target peptide. Immunity 2000;13:433-42.
100. Permanne B, Adessi C, Saborio GP, et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J 2002;16:860-2.
101. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76.
102. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9.
103. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995;1:143-8.
104. Palha JA, Ballinari D, Amboldi N, et al. 4′-Iodo-4′-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol 2000;156:1919-25.
105. Sebastiao MP, Merlini G, Saraiva MJ, Damas AM. The molecular interaction of 4′-iodo-4′-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation. Biochem J 2000;351:273-9.
106. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracydine 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995;92:2959-63.
107. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995;86:855-61.
108. Gertz MA, Lacy MQ, Dispenzieri A, et al. A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 2002;9:24-30.
109. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
110. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-5.
111. Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 2002;5:Suppl 1:1055-7.
112. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002;3:824-8.
113. Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001;412:739-43.
114. Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000;157:1239-46.